NRX Pharmaceuticals Inc (NRXP) Q3 2024 Earnings Call Highlights: Significant Reduction in ... [Yahoo! Finance]
NRX Pharmaceuticals, Inc. (NRXP)
Company Research
Source: Yahoo! Finance
Research and Development Expenses: Decreased from $3.3 million in Q3 2023 to $0.6 million in Q3 2024. General and Administrative Expenses: Slight decrease from $2.5 million in Q3 2023 to $2.4 million in Q3 2024. Cash and Cash Equivalents: $1.6 million as of September 30, 2024. Additional Financing: Secured $5.4 million in tranche two of secured debt financing post-September 30, 2024. Net Loss for Nine Months: Reduced to $16.1 million in 2024 from $25.8 million in 2023. Research and Development Expenses for Nine Months: $5.2 million in 2024, down from $10.8 million in 2023. General and Administrative Expenses for Nine Months: Decreased to $10.9 million in 2024 from $12.3 million in 2023. Warning! GuruFocus has detected 2 Warning Signs with NRXP. Release Date: November 18, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript NRX Pharmaceuticals Inc ( NASDAQ:NRXP ) achieved a 74% reduction in net operating losses co
Show less
Read more
Impact Snapshot
Event Time:
NRXP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NRXP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NRXP alerts
High impacting NRX Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
NRXP
News
- NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Michael Abrams as Chief Financial Officer [Yahoo! Finance]Yahoo! Finance
- NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Michael Abrams as Chief Financial OfficerPR Newswire
- NRx Pharmaceuticals (NASDAQ:NRXP) Reports Third Quarter and Year to Date 2024 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- NRx Pharmaceuticals (NASDAQ:NRXP) Reports Third Quarter and Year to Date 2024 Financial Results and Provides Business UpdatePR Newswire
- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Conference Call to Discuss Third Quarter and Year to Date 2024 Financial Results to November 18, 2024PR Newswire
NRXP
Earnings
- 11/14/24 - Beat
NRXP
Analyst Actions
- 9/12/24 - Ascendiant Capital
NRXP
Sec Filings
- 11/20/24 - Form 8-K
- 11/15/24 - Form 8-K
- 11/14/24 - Form 10-Q
- NRXP's page on the SEC website